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Abstract
Background: The Cry6 family of proteins from Bacillus thuringiensis represents a group of powerful toxins with
great potential for use in the control of coleopteran insects and of nematode parasites of importance to agriculture.
These proteins are unrelated to other insecticidal toxins at the level of their primary sequences and the structure
and function of these proteins has been poorly studied to date. This has inhibited our understanding of these
toxins and their mode of action, along with our ability to manipulate the proteins to alter their activity to our
advantage. To increase our understanding of their mode of action and to facilitate further development of these
proteins we have determined the structure of Cry6Aa in protoxin and trypsin-activated forms and demonstrated a
pore-forming mechanism of action.
Results: The two forms of the toxin were resolved to 2.7 Å and 2.0 Å respectively and showed very similar
structures. Cry6Aa shows structural homology to a known class of pore-forming toxins including hemolysin E from
Escherichia coli and two Bacillus cereus proteins: the hemolytic toxin HblB and the NheA component of the non-
hemolytic toxin (pfam05791). Cry6Aa also shows atypical features compared to other members of this family,
including internal repeat sequences and small loop regions within major alpha helices. Trypsin processing was
found to result in the loss of some internal sequences while the C-terminal region remains disulfide-linked to the
main core of the toxin. Based on the structural similarity of Cry6Aa to other toxins, the mechanism of action of the
toxin was probed and its ability to form pores in vivo in Caenorhabditis elegans was demonstrated. A non-toxic
mutant was also produced, consistent with the proposed pore-forming mode of action.
Conclusions: Cry6 proteins are members of the alpha helical pore-forming toxins – a structural class not previously
recognized among the Cry toxins of B. thuringiensis and representing a new paradigm for nematocidal and
insecticidal proteins. Elucidation of both the structure and the pore-forming mechanism of action of Cry6Aa now
opens the way to more detailed analysis of toxin specificity and the development of new toxin variants with novel
activities.
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Background
Bacillus thuringiensis strains produce a range of toxins
active against invertebrates with enormous potential for
use in the control of pests of importance in agriculture
and health [1]. During sporulation, strains synthesize
cytolytic (Cyt) toxins and/or crystal (Cry) protoxins and
deposit them as parasporal inclusion bodies. Of the 74
major subclasses of Cry protoxin currently recognized
(see http://www.lifesci.susx.ac.uk/home/Neil_Crickmore/
Bt/) [2], most belong to a large family of related se-
quences that can be proteolytically processed to yield ac-
tive toxins with a three-domain fold as first seen for
Cry3Aa [3]. However, the Cry nomenclature is not lim-
ited to these proteins and includes several distinct and
unrelated lineages. While much is known of the struc-
ture and function of the three-domain toxins [4] and the
structure of a protoxin form has recently been published
[5], very little is known of the non-three-domain Cry
proteins. Some of these proteins share sequence hom-
ology to other known toxins; for example, Cry35 and
Cry36 are related to the Bin and Cry49 toxins of Lysini-
bacillus sphaericus [6] and may share a proposed mech-
anism of action involving pore formation [7] and/or
apoptosis [8]. The structures of the ß-sheet-rich toxins
Cry45 (Parasporin4) [9], Cry46 (Parasporin 2) [10], and
recently Cry51 [11] and the Cry34/Cry35 binary toxin
[12] have been published but for many non-three-
domain Cry proteins, neither structural data nor infor-
mation on mechanism of action are available. One such
Cry protein is Cry6Aa [13], a protein with activity
against Coleoptera such as the Western Corn Rootworm
Diabrotica virgifera virgifera [14] and a range of nema-
todes, including both free-living (Caenorhabditis elegans
and Panagrellus redivivus) and plant pathogenic (Hetero-
dera glycines and Meloidogyne incognita) species [15–18]
that cause large-scale losses to agriculture [19].
Previous studies have shown by deletion of Cry6Aa
sequences that 10 amino acids can be deleted from the
N-terminus and 93 residues can be removed from the
C-terminus, leaving a core region of ~43 kDa that re-
tains activity against nematode targets [15]. Cry6B is a
protein that is closely related to Cry6A but lacks 88
amino acids that are seen at the C-terminus of the latter
protein. Cry6B is reported to be active against the cole-
opteran lucerne weevil Hypera postica [20] but showed
little or no activity against a range of nematode targets
[15]. The absence of further data on the structure and
function of these proteins has limited our ability to
understand their activity against target invertebrates. As a
result, development and exploitation of the toxins in the
control of agricultural pest insects and nematodes patho-
genic to plants and animals may be limited. This, in turn,
inhibits their use to supplement the current chemothera-
peutic approaches to nematicidal treatments that are very
toxic and are being phased out [21]. In this study we ap-
plied both crystallographic techniques and state of the art
ab initio modeling to probe the structure of Cry6Aa in
protoxin and trypsin-cleaved forms. The structures ob-
tained are novel among invertebrate-active toxins and are
consistent with Cry6Aa acting as a pore-forming toxin.
We demonstrated pore formation in vivo and used our
predictions to construct a mutant expected to show com-
promised toxicity.
Methods
Bacterial strains
B. thuringiensis strain BMB171 containing the pHT304-
derived plasmid encoding the Cry6Aa2 protein [22] was
kindly provided by Dr Ming Sun, Huazhong Agricultural
University, Wuhan, China. This strain was grown to
greater than 98 % autolysis (as judged by phase contrast
microscopy) in Embrapa medium [23]. Spores were har-
vested and crystals of Cry6Aa were isolated and purified
by discontinuous sucrose density gradient ultracentri-
fugation according to previously described methods
[6]. Cry6Aa protein crystals purified by this method
were solubilized at 37 °C with shaking at either alka-
line pH by incubation in 50 mM NaOH (final
pH 12.7) or at acidic pH by the addition of 100 mM
sodium citrate buffer pH 3.0.
Toxin production in Escherichia coli
The cry6Aa gene was amplified from the above B. thur-
ingiensis strain by 30 cycles of PCR with a 60 °C anneal-
ing temperature, using forward (5′-GTCGACGAATTCA
ATGATTATTGATAGTAAAACGAC-3′) and reverse
(5′-GTCGACGAATTCACAATTAATTATTATACCAAT
CCG-3′) primers, incorporating EcoRI restriction sites
(shown in italics). The amplicon was cloned into the
pGEM-T vector (Promega, Southampton, UK) and trans-
formed into E. coli DH5α for the selection of a single
colony, plasmid isolation, and sequencing to confirm the
cloning of the gene with no mutations. The gene was
subsequently cleaved from this plasmid with EcoRI and
re-cloned into the EcoRI site of the pET28b expression
vector to allow production of recombinant Cry6Aa
protein with an N-terminal His-tag. A mutation of the
cry6Aa gene to change Leu259 to Asp was introduced
using the Phusion site-directed mutagenesis kit
(ThermoFisher Scientific, Loughborough, UK) according
to the manufacturer’s instructions by PCR (98 °C for
30 s, followed by 25 cycles of 98 °C for 10 s, 57 °C for
30 s, and 72 °C for 200 s) using the pET28b clone as
template and the following 5′-phosphorylated oligonu-
cleotides: 5′-GACTTAGGATTTGTTGTTTATGAAAT
TC-3′ (TTG to GAC mutation shown in italics), 5′-
TGGTCCTAATAGAAAACTATATTC-3′. Following lig-
ation of the PCR product and transformation of E. coli
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DH5α, a colony was picked and the plasmid sequence
was verified to ensure incorporation of the desired mu-
tation and no other changes.
For recombinant production of Cry6Aa proteins in E.
coli, the pET28b plasmids were transformed into the
Shuffle T7 Express LysY E. coli strain (New England Bio-
labs, Hitchen, UK) and isolated colonies were selected.
Transformants were grown in lysogeny broth (LB)
medium in the presence of 50 μg/ml kanamycin at 37 °C
with shaking overnight before the addition of isopropyl
ß-D-thiogalactopyranoside (IPTG) to a final concentra-
tion of 1 mM and growth for a further 3 h. Expression
was verified by western blotting using monoclonal anti-
polyhistidine antibody (Sigma-Aldrich, Gillingham, UK:
Catalog code H1029 RRID:AB_260015) as the primary
antibody and rabbit anti-mouse alkaline phosphatase
conjugate antibody (Sigma-Aldrich: Catalog code A4312,
batch number 095 K4758) as the secondary antibody to
allow visualization of the proteins using the AP Conju-
gate Substrate Kit (Bio-Rad, Hemel Hempstead, UK).
For in vivo pore formation assays, a distinct clone
of the cry6Aa gene in the BamHI and PstI sites of
the vector pQE9 was produced (adding an N-terminal
His-tag and a seven amino-acid extension to the C-
terminus, encoded by the vector). An equivalent clone
in pQE9 containing the cry5Ba gene as a positive
control for in vivo pore formation has been described
previously [24].
Cry6 production in Pseudomonas fluorescens
For inclusion body (IB) preparation, Pseudomonas fluor-
escens-derived cell paste expressing full-length, wild-type
Cry6Aa1 (from Dow AgroSciences [GenBan-
k:AAA22357]) was transferred from −80 °C storage to
4 °C and resuspended at 20 % w/v in cold lysis buffer
[50 mM TrisHCl, 200 mM NaCl, 10 % glycerol, 0.5 %
Triton X-100, 20 mM EDTA, 1 mM Tris(2-carbox-
yethyl)phosphine (TCEP), pH 7.5] and mixed thoroughly
with a handheld homogenizer. The suspension was then
passed through a Microfluidizer (Microfluidics M-
110EH) twice at 16,000 psi then centrifuged (SLC-6000
rotor, 14,000 g for 40 min at 4 °C). The supernatant was
discarded. The IB pellet was fully resuspended by
homogenization in 10 % w/v room temperature lysis
buffer with 0.4 g/l lysozyme (L-6876; Sigma-Aldrich).
The suspension was incubated at 30 °C for 30 min, with
brief homogenization every 10 min. The IBs were then
centrifuged (SLC-6000 rotor, conditions as above) and
the supernatant was discarded. The pellet was resus-
pended for a final time in 10 % w/v cold lysis buffer
using the homogenizer and then centrifuged (SLC-6000
rotor, conditions as above) and the supernatant dis-
carded. The IB pellet was resuspended in 10 % w/v cold
lysis buffer without Triton X-100 (50 mM TrisHCl,
200 mM NaCl, 10 % glycerol, 20 mM EDTA, 1 mM
TCEP, pH 7.5) using the homogenizer and then centri-
fuged (SLC-6000 rotor, conditions as above) and the
supernatant discarded. This step was repeated twice.
The IBs were resuspended to 30 % (w/v) in 10 mM
EDTA, pH 8.0, and then separated into 1.5 ml aliquots
and frozen at −80 °C until needed. A separate aliquot of
the IB preparation was stored without suspension in
10 mM EDTA.
Purification of full-length Cry6Aa
About 500 mg of Pseudomonas-derived IB paste was
thawed at 4 °C, and centrifuged at 23,000 g for 25 min
at 4 °C. The supernatant was removed and the pellet
was solubilized in 30 ml of 100 mM CAPS, pH 11.0, and
the suspension was gently rocked for 2 h at room
temperature to solubilize the Cry6Aa. After
solubilization, the mix was centrifuged at 23,000 g for
25 min at 4 °C. The supernatant was dialyzed against
25 mM CAPS, pH 10.0, overnight.
The buffer exchanged Cry6Aa sample was then filtered
through a 0.22 μm syringe filter and applied to a Source
15Q 16/6 ion exchange column at a flow rate of 5 ml/
min. The column was pre-equilibrated with buffer A
(25 mM CAPS, pH 10). The protein was eluted with a
step gradient of 20 %, 30 %, 40 %, and 50 % buffer B
(buffer A + 1 M NaCl). Each elution was ~50 ml. Frac-
tions were collected from each elution based on UV ab-
sorbance and analyzed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). Full-
length Cry6Aa (475 amino acids) was in the 20 % B frac-
tions, which were pooled and concentrated to ~30 ml
using a centrifugal filter device with 10 kDa molecular
weight cut-off membrane (Millipore, Cal# UFC901024).
The concentrated sample was further purified by size
exclusion chromatography. For each run, 4.0 ml of the
sample was applied over a Superdex 75 26/90 gel filtra-
tion column pre-equilibrated in 25 mM CAPS, pH 10,
and 50 mM NaCl buffer, at a flow rate of 2.5 ml/min.
Two peaks were observed (monitored by absorbance at
280 nm). The first peak, eluted at the void volume, con-
tained Cry6Aa dimers (judged by non-denaturing and
denaturing SDS-PAGE, with only monomers of Cry6Aa
appearing in the latter case). The fractions from peak 2
contained predominantly monomer and were pooled
and used in crystallization experiments.
Purification of Cry6Aa trypsin-resistant core
Eight 2 ml tubes of IB suspension of full-length Cry6Aa
were thawed and extracted in 80 ml final volume (1:5 di-
lution) of 10 mM CAPS, pH 11.0. The measured pH of
9.1 was then adjusted to 11.0 with NaOH. Freshly pre-
pared trypsin [2 ml of 25 mg/ml trypsin solution (Sigma,
T1426-1G TLCK treated] in 1 mM HCl, 5 mM CaCl2)
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was added, the pH was maintained at 11.0, and the mix-
ture was stirred overnight at 4 °C.
The digestion was applied to a Source 15Q 16/10 col-
umn pre-equilibrated in buffer C (25 mM CAPS,
pH 11.0) at a flow rate of 10 ml/min and eluted with a
gradient of buffer C + 1 M NaCl over 75 min. Trypsin-
processed Cry6Aa eluted as a single large peak, which
was concentrated from 100 ml to 10 ml using 15 ml
Amicon 10,000 MWCO spin concentrators in a JA-12
rotor at 4 °C and 5000 g.
The concentrated ion exchange sample was applied to
a Superdex 75 26/90 gel filtration column pre-
equilibrated in 25 mM CAPS, pH 11.0, and 50 mM
NaCl. The sample was eluted using a 2.5 ml/minute flow
rate. The fractions corresponding to the large Cry6Aa
core peak were pooled (80 ml at 2.05 mg/ml) for
crystallization trials.
Secondary structural analysis
Circular dichroism (CD) spectra were recorded using a
JASCO J-815 CD spectrometer equipped with an
MPTC-490S 6-cell Peltier Thermostatted cell holder.
The instrument was calibrated with (1S)-(+)-10-cam-
phorsulfonic acid. Measurements were carried out in a
1 mm path-length quartz cuvette under a constant nitro-
gen stream and at room temperature (25 °C). Data were
collected in continuous scan mode from 260 to 185 nm
every 0.5 nm at 50 nm/min and with 2 s averaging per
point. Each spectrum is the average of five accumula-
tions and a bandwidth of 1 nm. The concentration of
Cry6Aa1 protein in 10 mM phosphate pH 3.0 was 0.09
mg/ml, in 10 mM phosphate pH 8.0 was 0.09 mg/ml,
and in 10 mM CAPS pH 11.0 was 0.085 mg/ml. All
spectra were corrected for the buffer contributions and
the raw data output in ellipticity (θ), measured in milli-
degrees (mdeg) was converted to mean residue ellipticity
(MRE, i.e., [θ] MRW) in deg cm
2/dmol using the instru-
ment software, Spectrum Manager 2. The CDPro pack-
age was used for secondary structure estimation using
the programs SELCON, CONTINLL, and CDSSTR. The
programs gave results that were similar to each other
and relatively independent of the reference protein set
used. The secondary structure calculations reported here
were from processed CD spectra using the CDSSTR al-
gorithm and the SP37A reference set.
Crystallization, data collection, and structure
determination
Cry6Aa trypsin-resistant core
The Cry6Aa trypsin-resistant core was concentrated to
100 mg/ml. Initial crystals were obtained using Rigaku
Reagents, Inc. Wizard Classic I (Bainbridge Island, WA,
USA). After screening multiple conditions, suitable crys-
tals were obtained under kit condition 39 [20 % (w/v)
PEG 1000, 0.1 M sodium phosphate dibasic/citric acid,
pH 4.2; 0.2 M lithium sulfate]. Data were collected at
100 K from a single crystal on a Mar CCD-300 detector
at LS-CAT (Advanced Proton Sources, Argonne Na-
tional Laboratory). Data were indexed and processed
with the HKL-2000 software suite [25].
The structure of this truncated form of Cry6Aa toxin
was solved by the molecular replacement method using
PHASER [26] (CCP4 package [27]) followed by manual
rebuilding and model refinement. The poly-alanine
chain of the crystal structure of hemolysin B from Bacil-
lus cereus [PDB: 2NRJ] consisting of residues 19–334
was used as a search model. The final structure of the
complex was obtained by carrying out several cycles of
refinement consisting of manual model building using
COOT [28], followed by restrained refinement with
REFMAC [29] using Translation, Libration and Screw-
rotation (TLS) refinement and the reference and second-
ary structure restraints. The trypsin-cleaved Cry6Aa
structure, solved at higher resolution, was used as the
reference structure in this refinement. Crystallographic
data and refinement statistics are given in Table 1 and
the Cry6A trypsin-resistant core structure can be found
at the Protein Data Bank [PDB: 5KUC].
Purification of full-length Cry6Aa
Full-length Cry6Aa protein was concentrated to 15 mg/
ml using Amicon centrifugal filters with a 10 kDa mo-
lecular weight cut-off (Millipore, USA) in 10 mM
HEPES buffer, pH 7.5 and 25 mM NaCl.
Initial crystallization screens were performed using
commercially available Classics, Classics Lite, Classics II,
PEGs, PEGs II, PhClear, and PACT screens (Qiagen) by
the sitting drop method in 96-round-bottom-well
crystallization plates (Greiner Bio-One, GmbH,
Germany) using a Mosquito Robotic System (TTP Lab-
Tech, Hertfordshire, UK). Diffraction quality Cry6Aa
protein crystals were grown at 291 K from sitting drops
containing 3 μl of the protein sample and 1.5 μl of reser-
voir solution (0.1 M citric acid, pH 4.6, 4 % PEG 6000).
SDS-PAGE analysis of protein samples obtained by dis-
solving the crystals in SDS-buffer did not reveal any deg-
radation products and confirmed the presence of only
full-length Cry6Aa protein in the crystals used for the
data collection.
For data collection, crystals were harvested with 20 %
(v/v) glycerol in the reservoir solution. Diffraction data
were collected at 100 K from a single crystal on a Mar
CCD-300 detector at LS-CAT (Advanced Proton
Sources, Argonne National Laboratory). Data were
indexed and processed with HKL-2000 [25]. The crystals
belonged to orthorhombic space group P21212 and
contained one molecule of full-length Cry6Aa per asym-
metric unit.
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The structure of full-length Cry6Aa was solved by mo-
lecular replacement using the structure of the truncated
form of Cry6Aa as a search model. The final structure of
full-length Cry6Aa toxin was obtained by carrying out
several cycles consisting of manual model building using
COOT [28], followed by structure refinement with
REFMAC [29]. Crystallographic statistics are given in
Table 1. Coordinates have been deposited in the Protein
Data Bank [PDB: 5KUD].
Molecular modeling
The Cry6Aa tertiary structure was modeled ab initio
using the Rosetta software [30]. After entering the
Cry6Aa sequence, the first stage of the web-based
process returned a secondary structure prediction with
options to continue full protein structure prediction
either using de novo or database structure comparison
methods. Both methods were followed to produce a se-
lection of five possible structure outcomes from both de
novo and database predictions (10 models in total).
Intact molecular weight analysis/charged state distribution
Intact mass analysis was performed on an Agilent 1200
HPLC/MSD TOF 1969A system using a Michrom
desalting trap heated to 50 °C. Each sample was diluted
to a concentration of 0.2 μg/μl in 10 mM CAPS pH 11
buffer. Samples were also analyzed after reduction with
50 mM TCEP for 10 min. Approximately 1 μg protein
was injected on column. The sample was eluted using a
gradient (10 % buffer D for 1 min, 10–60 % buffer D
over 2 min, 60–98 % buffer D over 2 min, 10 % buffer D
for 1 min), where buffer A is 0.1 % formic acid in water
Table 1 Data collection and refinement statistics
PDB code Cry6Aa trypsin-cleaved 5KUC Full-length Cry6Aa 5KUD
Data collection
Wavelength (Å) 1.12675 0.9786
Resolution range (Å) 50.00–2.00 (2.07–2.00)a 50.00–2.70 (2.80–2.70)
Space group P 65 P 21 21 2
Cell dimensions
a, b, c (Å) 112.967, 112.967, 76.627 50.367, 71.735, 142.913
α, β, γ (°) 90.0, 90.0, 120.0 90.0, 90.0, 90.0
Total reflections 135,786 97,894
Unique reflections 37,186 (3343) 14,755 (1454)
Multiplicity 3.7 (2.3) 6.6 (7.1)
Completeness (%) 98.80 (89.40) 99.50 (100.00)
< I>/sigma(I) 33.41 (4.51) 10.98 (2.88)
R-mergeb (%) 6.1 (22.9) 14.6 (89.4)
Refinement
Resolution range (Å) 30.01–2.00 (2.06–2.00) 29.14–2.70 (2.80–2.70)
R-work/R-freec (%) 18.77 (25.10)/22.80 (27.98) 27.43 (33.62)/32.48 (43.45)
Number of non-hydrogen atomsd 3605 3027
protein 3183 3006
ligand 0 0
water 422 21
Protein residues 402 393
RMS, bonds (Å) 0.009 0.013
RMS, angles (°) 1.071 1.650
Ramachandran favored (%) 98.74 97.93
Ramachandran outliers (%) 0.25 0.26
Average B-factor 30.70 84.00
PDB Protein Data Bank, RMS Root Mean Square deviation from ideal values (crystallography)
aStatistics for the highest-resolution shell are shown in parentheses
bRmerge = 100Σ(h)Σ(i)|I(i)-<I>|/ Σ(h)Σ(i)I(i) where I(i) is the ith intensity measurement of reflection h, and <I> is the average intensity from multiple observations
cRfactor = Σ||Fobs|-|Fcalc||/ Σ|Fobs|. Where Fobs and Fcalc are the structure factor amplitudes from the data and the model, respectively. To calculate R-free values, 5 %
and 10 % reflections were used for Cry6Aa trypsin core and full-length Cry6Aa structures, respectively.
dPer asymmetric unit
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and buffer D is 70 % isopropanol, 20 % acetonitrile, 10 %
water, and 0.1 % formic acid. The mass was calculated
using the Mass Hunter Qualitative Analysis software and
the maximum entropy de-convolution algorithm.
Changes in the observed charge state distribution
(CSD) of proteins analyzed by liquid chromatography–
mass spectrometry (LC-MS), as described above, were
used as an indirect probe of the overall conformational
flexibility of the protein under different conditions.
MALDI-TOF mass spectrometry and tandem mass
spectrometry
Digestion of Cry6Aa with trypsin results in two fragment
fractions, a large fragment and a small fraction containing
two peptides. The small fragment sample was analyzed by
matrix-assisted laser desorption/ionization - time of flight
mass spectrometry (MALDI-TOF/TOF MS) to determine
the peptide masses and was subsequently fragmented in
the LIFT mode to confirm the sequence of the peptides.
The MALDI-TOF MS and tandem mass spectrometry
(MS/MS) were conducted with a Bruker UltraFlextreme
mass spectrometer. The C-terminal peptide (CTP) sample
was diluted with 0.2 % trifluoroacetic acid (TFA) at 1:1 (v/
v) and desalted using a C-18 Ziptip (Millipore). The pep-
tides were eluted with 60 % acetonitrile (ACN) in 0.1 %
TFA and mixed with a 2,5-dihydroxybenzoic acid (DHB)
matrix [15 mg/ml in ACN:H2O (50:50)]. After spotting
1 μl of the mix on a MALDI sample plate, the peptide
mass was analyzed using reflection-positive mode and the
peptide was fragmented using the LIFT mode. The instru-
ment was calibrated with CM 2 (calibration mixture 2,
Peptide Mass Standards Kit, Applied Biosystems Sciex, P/
N P2-3143-00). The mass spectrum was collected and an-
alyzed using flex analysis software. The sequence was veri-
fied using BioTools software (Bruker) and the MASCOT
search engine (Matrix Science).
N-terminal sequencing
Amino terminal sequencing of proteins was performed
on a Shimadzu Protein Sequencer (Model PPSQ-33A)
using basic Edman degradation chemistry. The protein
sample was separated with SDS-PAGE under reducing
conditions, and then the proteins were blotted onto
polyvinylidene difluoride (PVDF) membrane by liquid
transfer. A standard mix of 20 phenylthiohydantoin-
amino acids (Shimadzu, catalog# 013-08391) was run
each time. The amino acid residues from each Edman
degradation cycle were determined based on their
retention times from the C-18 column compared to
standards.
Nematode bioassay
C. elegans Bristol N2 strain wild-type nematodes (C. ele-
gans Genetic Stock Center) were cultured using standard
techniques including the use of E. coli strain OP50 (C.
elegans Genetic Stock Center) as standard food source
[31] on enriched nematode growth (ENG) plates [32]
containing 100 μM IPTG and 50 μg/ml kanamycin
(ENG-IK plates [32]). To measure intoxication by
Cry6Aa, 30–40 fourth-staged larvae of C. elegans were
seeded on ENG-IK plates with E. coli Shuffle T7 Express
LysY cells (New England Biolabs) transformed with the
pET28b empty vector (negative control) or pET28b with
cry6Aa inserts (wild-type and mutant forms) and incu-
bated at 25 °C for 24 h. Three replica plates were used
for each strain. Three to five worms were randomly
picked from each of the different treatment conditions
for image collection. Worm growth was assessed by
measuring the area of clearly separated, individual
worms (worms overlapping on image collection were
not measured), using Image J (version 1.46r) and
MATLAB (version R2010a) software [32]. The experi-
ment was independently repeated three times. Data were
analyzed with JMP v. 11 using one-way ANOVA and
Dunnett’s post-test using the vector as the control
group.
In vivo pore formation assay
Pore formation was assessed microscopically using the
method described by Los et al. [24]. C. elegans Bristol
N2 strain nematodes were synchronized by hypochlorite
treatment. L1 animals were seeded onto OP50 and
grown at 20 °C until the L4 stage was reached. E. coli
JM103 cultures (ATCC) transformed with the empty
pQE9 vector or vectors for expression of Cry5Ba or
Cry6Aa were grown overnight at 37 °C with shaking in
LB medium containing ampicillin. These cultures were
diluted 1:10 in fresh medium and grown at 37 °C with
shaking for 1 h before addition of IPTG to 50 μM and
further incubation at 30 °C for at least 3 h with shaking.
After this induction of protein expression, 30 μl of these
cells, concentrated to an optical density of 2, were
spread onto 60 mm diameter ENG agar plates contain-
ing ampicillin and IPTG and allowed to grow overnight
at 25 °C for use in assays. Worms were then washed off
the OP50 plate, washed twice to remove bacteria, and
pipetted onto agar plates spread with the transformed
JM103. Plates were incubated for 2 h at 20 °C. Worms
were then washed off the plates, washed twice in M9
medium to remove bacteria, and rotated end-over-end
at room temperature in M9 medium containing 5 mg/
ml 5-hydroxytryptamine (serotonin, Sigma) for 15 min
to stimulate feeding. Propidium iodide was then added
to the medium and worms were rotated for an additional
30–40 min. Worms were washed twice to remove excess
dye and pipetted onto agar pads on microscope slides
and imaged. Pictures were taken using a Spot Insight
CCD camera and Spot software connected to an
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Olympus BX60 compound microscope with an UplanFl
40×/0.75NA objective. At least 30 worms were imaged
for each condition, and the entire experiment was con-
ducted three times. The percentages for all three experi-
ments were combined and analyzed by one-way
ANOVA followed by Dunnett’s multiple comparison test
between each toxin and the no-toxin control, using
GraphPad Prism.
Results and discussion
Initial analysis
The Cry6Aa protein is active in the gut of nematodes
such as C. elegans, which is an acidic environment with
a pH ranging from ~3.6 to 6.0 [33] or Coleoptera such
as Diabrotica virgifera virgifera with pH ranging from
5.75 to 6.03 [34]. The Cry6Aa crystals produced in B.
thuringiensis and purified by sucrose gradient centrifuga-
tion could be solubilized at pH 10.0; however, Cry6Aa
derived from this source showed a tendency to form ag-
gregates and to precipitate after solubilization at either
pH 3.0 or 12.7, particularly if this solubilization was
followed by neutralization. As a result, further analyses
utilized recombinant Cry6Aa produced in P. fluorescens.
The secondary structure content of the full-length
Cry6Aa protein from this source was estimated through
CD analysis. At pH 3.0, results indicated an alpha helical
content of ~73–74 % (depending on the protein refer-
ence used) with a beta sheet content of ~2–3.5 %. At
pH 8.0, helical content of ~70–72 % and beta sheet of
~1–2 % was indicated. Results at pH 11.0 were impacted
by the absorbance of the CAPS buffer below 200 nm
and, thus, are less reliable but suggest that the protein
remains predominantly alpha helical at this pH. Overall,
and considering the inherent margins of error in CD de-
terminations, these results suggest that the protein has a
stable secondary structure across a broad pH range of
3.0 to 11.0.
The structure of the trypsin-resistant core
The structure of the trypsin-resistant core (Fig. 1) ex-
hibits a group of long alpha helices (around 90 Å) that
are amphipathic in nature, with their hydrophobic sides
interacting and their hydrophilic faces showing greater
exposure to solvent. This helix bundle is around 20–
25 Å in diameter with a head domain folded across the
helices at one end, formed from residues close to the C-
terminus of the protein. The Cry6Aa trypsin-resistant
core structure is unlike any previously described Cry
protein although it is similar to several known toxins, in-
cluding HlyE and HblB (see below).
Fig. 1 Crystal structure of Cry6a toxin. Ribbon representation of trypsin-truncated Cry6Aa form showing two domain architecture: the “tail” domain
consists of one helical bundle with five long α-helices, labeled αA, αC, αD, αG, and αH, and shorter helices, labeled αB, αE, αF, and αI; while several long
and short loops form the “head” domain. N- and C-termini and the putative transmembrane region are labeled. The Cys88-Cys451 disulfide bond is
shown and, in the insert box, the final 2Fo-Fc electron density map calculated at 1.5σ in the region of this bond is shown in blue mesh. Side and main
chains of the amino acid residues are presented as sticks and colored by the atoms
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Analysis of the trypsin-resistant core by SDS-PAGE
following reduction and Edman degradation of the major
band showed the N-terminal sequence HSLIH, corre-
sponding to residues 12–16 of the Cry6Aa sequence and
indicating processing after Arg11. Analysis by mass
spectrometry of the trypsin-processed toxin, purified by
ion exchange chromatography, without reduction,
showed a dominant species with a mass of 46,844.19 Da
and a minor species of 45,995.25 Da. The deconvoluted
intact average molecular weight (MWavg) value of
46,844.19 Da matches the theoretical value (46,843.43 Da)
expected for a core protein containing polypeptide chain
12–390 disulfide bonded to chain 444–475 with a mass
error of +16.2 ppm. The minor species with MWavg of
45,995.25 matches the theoretical value of 45,996.51 for a
core protein containing polypeptide chain 12–390 disul-
fide bonded to chain 451–475 with a mass error of
+16.1 ppm. The mass errors for both of these measure-
ments are within the expected mass accuracy of the LC-
TOF instrument. The two CTPs, m/z 4114.894 and
3266.38 Da, were sequenced by MALDI MS/MS.
This confirmed that the 4114.894 peak had the sequ-
ence NSNLEYKCPENNFMIYWYNNSDWYNNSDWYNN
(italicised residues were identified and assigned), which
matched the CTP1 sequence of residues 444–475. The
3266.38 peak had the sequence CPENNFMIYWYNNSD
WYNNSDWYNN, which matched the CTP2 sequence
from residues 451–475. These results show trypsin cleavage
after Arg390 and processing sites after Arg443 and, at a
lower frequency, after Lys450.
The solved structure of the trypsin-activated Cry6Aa
corresponds to the major core of the toxin with the lon-
ger CTP1 fragment (from Asn444 to Trp472) still linked
to the main body of the toxin by a disulfide bond. This
bond can be clearly resolved in the structure (Fig. 1, in-
sert). However, several residues were not resolved in the
activated toxin structure: CTP1 residues Asn444 and
Tyr473-Asn475; core region residues Lys126-Lys127 and
Asn388-Ser389-Arg390, indicating that these regions are
not fixed in the structure.
The structure of full-length Cry6Aa
The full-length structure of Cry6Aa [PBD: 5KUD] is
slightly less structured than that of the trypsin-resistant
core and was solved to a lower resolution (refinement
statistics provided in Table 1). In the ordered regions
where electron density can be traced, the structures are
almost identical with a root mean square deviation
(RMSD) for C-alpha atoms (total 391 matches after
alignment) of 0.633 Å (Fig. 2a).
Mass spectrometric analysis of the full-length Cry6Aa
used in crystallization revealed a deconvoluted molecular
mass of 54,072.1 Da and, following reduction with dithio-
threitol (DTT), a mass of 54,075.8 Da, corresponding to
single full-length protein chain from Met1 to Asn475 and
containing two disulfide bonds, as revealed by the mass
difference of 4 between reduced and non-reduced states.
The N-terminal 11 amino acids, the C-terminal six resi-
dues, Lys126–Lys127, and the region from Asn388 to
Lys450 were not resolved, indicating significant flexibility
Fig. 2 Comparison of Cry6Aa structures. a Superimposed ribbon representations of the crystal structures of the truncated (cyan) and the full-length
(magenta) Cry6Aa forms. b The full-length Cry6Aa model is shown with the following features illustrated: wing-like intra-helical loops (red); putative
transmembrane region (orange) with L259 shown in stick representation; WATIGAxI repeat sequence (green); TTNMTSNQY repeat sequence (cyan);
WYNNSDWYNNSDW repeat (magenta); and the modeled Asn388–Lys450 in dark gray and cyan
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in these regions. The latter region contains the trypsin cut
sites described above and the flexibility of this region may
contribute to its accessibility to this enzyme. The sequence
from Cys451 to Asn469 is clearly seen in the structure
and appears to be held in place by a disulfide bridge be-
tween Cys88 and Cys451 (see below).
To understand the activity of Cry6Aa from a struc-
tural point of view, and because some regions were
unresolved in the structure, modeling was carried out
to determine the conformation of internal missing
segments and to build a full-length structure model.
The Loop Modeler in MOE (Molecular Operating En-
vironment, Chemical Computing Group, Montreal,
Quebec, Canada) was used to find and select loop
candidates using the PDB engine and to build model
loops based on the desired loop sequence. After
selecting a set of backbone loop candidates from the
PDB loop library, optimization proceeded, including
addition of side chains and a multi-stage energy
minimization with pre-defined refinement protocols.
The two regions Lys126–Lys127 and Asn388–Lys450
were modeled manually using COOT as described
above to produce a structure-based model of residues
12–472. Ser386 and Tyr449 in the crystal structure
were used as anchor residues and the region from
residue 387 to 450 was used as the desired sequence
to determine loop length and geometry restrictions.
The loop searching calculation resulted in several
model loops. The best model loop was chosen, based
on its positioning of Cys88 and Cys451 in close prox-
imity (consistent with the fact that they are disulfide-
linked) and placing Cys402 close to Cys404, consider-
ing that the mass spectroscopy study indicated
another disulfide bond. The two pairs of Cys residues
were manually connected, followed by an energy
minimization with MMFF94x force field. The result-
ing Cry6Aa model, from residue 12 to 472 (referred
to below as the full-length model) has an alpha helical
content of ~70 % and a beta sheet content of ~1.7 %, con-
sistent with the CD data for this protein.
During the initial sequence analysis performed as part
of this study, it was noted that the Cry6Aa sequence
contains several internally repeated sequences that have
not previously been noted. These can be visualized in the
full-length model (Fig. 2b). The C-terminal domain con-
tains two of these repeats: the sequence TTNMTSNQY
(residues 406–414 and 418–426; cyan in Fig. 2b) and the
repetitive sequence WYNNSDWYNNSDWYNN forms
the extreme C-terminus of the protein (part of which
is visible in the structure; magenta in Fig. 2b). The
other repeat sequence, WATIGAxI(E/Q), occurs at
residues 44–52 then at 332–340 and contributes to
different alpha helices within the active core of the
toxin (green in Fig. 2b).
Disulfide bonding and conformational rigidity
The Cry6Aa sequence contains five Cys residues at posi-
tions 88 and 162 in the long alpha helical region, and at
positions 402, 404, and 451 in the C-terminal region.
The structures of the Cry6Aa trypsin-activated form and
full-length Cry6Aa model show that Cys88 forms a di-
sulfide bond with Cys451, while Cys402 appears to be
joined to Cys404. Cys162 is not disulfide bonded in
either full-length or activated Cry6Aa structures and it
appears to face into the core of the alpha helical bundle
where it is not surface exposed. The buried nature of
this residue was confirmed by mass spectrometric
analysis. Treatment of wild-type Cry6Aa under non-
denaturing conditions with iodoacetamide resulted in no
shift in deconvoluted intact average molecular weight,
indicating that it is not accessible to modification. When
the same protein was pre-treated with DTT followed by
iodoacetamide, a mass change consistent with reduction
of two disulfide bonds and alkylation of four cysteine
residues was observed, suggesting that Cys162 remains
inaccessible despite the overall increased structural flexi-
bility caused by reduction of disulfide bonds.
The conformation of the Cry6Aa protein was also
probed by mass spectrometry. Ionization of intact pro-
teins under electrospray mass spectrometry conditions
resulted in the detection of multiply charged species
with characteristic CSDs unique for each protein. The
distribution of charges (H+) on a protein under the de-
naturing conditions used for LC-MS is influenced by the
primary sequence and the conformational flexibility of
the protein, which determines the available protonation
sites exposed on the denatured protein surface. This
characteristic behavior of proteins is routinely used as
an indirect probe of the flexibility of protein tertiary
structure [35]. The role of the disulfide bonds in the
overall rigidity of Cry6Aa was probed by measuring the
CSD under different conditions (Fig. 3). Comparison of
the CSD for Cry6Aa under non-reducing conditions and
after treatment with 1 mM DTT shows a profound shift in
the CSD (Fig. 3a and b), even though the deconvoluted in-
tact average molecular weight only increased by +4. Under
non-reducing conditions, the CSD is centered around m/z
1690.84, corresponding to a +32 charge state. After reduc-
tion, the CSD shifts to a center around m/z 1021.34, cor-
responding to a +53 charge state. This shift towards
more highly charged species is a reflection of the de-
creased rigidity of the overall protein tertiary struc-
ture resulting from the reduction of the disulfides
with DTT, exposing additional protein surfaces to
protonation during ionization.
The pairing of cysteine residues and the buried nature of
Cys162 described above indicate that natural Cry6Aa crys-
tals are not stabilized by intermolecular disulfide bonds.
This contrasts with many three-domain Cry protoxins in
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which disulfide bonds between the C-terminal proparts of
individual protoxin molecules are important in crystal for-
mation [36]. However, while Cry6Aa crystal stability does
not appear to be mediated by covalent intermolecular
bonding, we can speculate that the rigidity conferred on
the Cry6Aa monomers by the intramolecular disulfide brid-
ges could be relevant to crystal packing.
Similarity to other toxins
It is interesting to note that in the related Cry6Ba se-
quence, the C-terminal domain found in Cry6Aa (88
amino acids shown in blue/cyan/magenta in Fig. 2b) is
absent. As a result, the Cry6Ba sequence will lack both
the C402–C404 and the C88–C451 disulfide bonds.
There is no Cys residue at the position equivalent to
Cys88 in a primary sequence alignment of Cry6Aa and
Cry6Ba, where this residue is Asn94 (Additional file 1:
Figure S1). Cry6Ba does, however, contain two additional
cysteine residues at positions 100 and 125 in helix αC
but these residues are too far apart to form an intramo-
lecular disulfide bond. Cry6Ba also lacks two of the
repetitive features described above (TTNMTSNQY re-
peat and C-terminal WYNNSD…) and the remaining
repeat feature in Cry6Aa (WATIGAxIQ/E) is changed in
both occurrences in Cry6Ba and becomes non-repetitive
(WAFVQAYVT, residues 50-58, and WSVISLNIG, resi-
dues 340–348; Additional file 1: Figure S1). Cry6Ba has
coleopteran activity but little or no nematode toxicity
[20]. This indicates that this region is not necessary for
toxicity per se. In the case of Cry6Aa, the C-terminal re-
gion is also not essential for toxicity since deletion of the
C-terminal 93 residues and the first 10 residues from the
N-terminus produces proteins that retain some, albeit
reduced, toxicity against C. elegans [15]. The “wing” fea-
tures seen in Cry6Aa (Fig. 1) are regions that vary in
length when compared to the equivalent regions in
Cry6Ba (Additional file 1: Figure S1). Since in Cry6Aa
these features form interruptions to the αC and αD heli-
ces, we predict that these variations will be well tolerated
in Cry6Ba.
The structures derived for Cry6Aa are striking in their
structural similarity to previously described bacterial
Fig. 3 Charge state distributions (CSDs) of Cry6Aa. a Under non-reducing conditions the CSD centers around m/z 1690.84. b Following treatment
with 1 mM dithiothreitol (DTT), the CSD centers around m/z 1021.34
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toxins. A DALI search [37] conducted with the trun-
cated Cry6Aa crystal structure identified the closest
structural homolog as the HblB component of the Bacil-
lus cereus hemolytic toxin [38] (pfam05791, [PDB:2NRJ])
with a significant Z-score value of 24.3 %, RMSD be-
tween 300 C∝-atoms of 2.8 Å and sequence identity of
12 % (Fig. 4a). The structural similarities to other toxins
– such as the NheA component of the B. cereus non-
hemolytic toxin [39] ([PDB: 4K1P], itself related to the
NheC component of this toxin) and hemolysin E from E.
coli [40] (HlyE, also known as ClyA or SheA [PDB:
4PHO]) – are also remarkable, with Z-scores of 21 %
and 11 %, and RMSD values of 3.5 Å and 4.3 Å, despite
low sequence identity of 12 % and 10 %, respectively
(Figs. 4b and c). These are pore-forming toxins, which,
like Cry6Aa, exhibit an elongated structure composed of
an alpha helical bundle with a head domain at one end.
Cry6Aa also shows some similarity to SMC_prok_A
family proteins that are also known to form dimers [41];
in the related HlyE crystal structure, two monomers can
be seen to pack together in a head-to-tail orientation
[40]. Dimeric forms of Cry6Aa were observed in this
study and have been described previously [14] but the
packing of the monomers is not known. Despite this,
there is no evidence for dimer formation in either crystal
structure.
It is interesting to note that in Cry6Aa, two of the long
alpha helices are interrupted with surface loops (shown
in red in Fig. 2b) bounded by Gly residues
(G121DPSIKKDG129 and G189DQKKLEG196):; the first of
these loops is also seen in the ab initio models although
the second was not predicted. These small, wing-like
intra-helical loops are a unique feature of Cry6Aa not
seen in the related structures of HlyE, HblB, or NheA
Fig. 4 Comparison of Cry6Aa structure with structures of other related toxins. Superposition of Cry6Aa (cyan) with a HBL-B (yellow), b NheA (gray), and
c HlyE (orange). In panel d, the surface representation of hydrophobic areas of the truncated Cry6Aa in ribbon representation are colored green and
the remaining residues are colored gray. The putative transmembrane region is labeled (TM). C-terminal 463–472 residues are removed for simplicity
Fig. 5 Nematode bioassay: C. elegans were fed on E. coli transformed
with the pET28b plasmid as a negative control (Vector); transformed
with this vector containing the wild-type cry6Aa gene (Cry6Aa); or
transformed with the vector with the L259D mutant of this gene
(L259D). a Images of some nematodes chosen at random are shown
and b results are presented as mean worm area (12 worms per bar,
each bar average from three independent experiments). p values
comparing each condition to vector control are shown. Error bars
represent the standard errors of the means
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and their significance is unknown at present. They do
not appear to significantly interact with the rest of the
molecule and residues Lys126 and Lys127 are not visible
in the crystal structures, suggesting that they are mobile.
Despite their apparent surface accessibility and the two
lysine residues found near the tips of both of these
loops, trypsin does not appear to cleave at these sites
(described above). The HlyE mode of action model of
Mueller et al. [42] and the recent work of Benke et al.
[43] propose that upon interaction with the membrane,
the putative pore-forming tongue region unfolds, caus-
ing the alpha helices to extend. It is possible that a simi-
lar rearrangement may occur for Cry6Aa, and that the
G121DPSIKKDG129 and G189DQKKLEG196 loops recon-
figure into alpha helical segments. This hypothesis is
consistent with the observation that each loop is seven
amino acids in length (two helical turns) and is bounded
by glycine residues, which, due to the hydrogen R group,
allow free rotation around the peptide bond, allowing a
low energy secondary structure transition.
The head domain of Cry6Aa is folded across the heli-
ces as seen in the HblB [44] and NheA [39] structures
(an orientation known to be somewhat distinct from that
in HlyE [40]). Within the head domains of these proteins
is a region termed the beta tongue that may contain the
transmembrane sequence that allows them to form
pores in target cells [38, 40, 44, 45]. In HlyE, this puta-
tive membrane-spanning in the beta tongue [46] is pro-
posed to insert into the membrane along with the
flanking helix E [45] to produce an oligomeric pore from
either eight [47] or 13 [48] monomers. A similar hairpin
loop feature, well conserved in Cry6Ba (Additional file 1:
Figure S1) (residues 250–268, VEYSFLLGPLLGFV-
VYEIL) was identified both in the ab initio models and
the structures of Cry6Aa (Fig. 4d and orange in Fig. 2b);
analysis using the TMPRED software [49] predicts this
to be a candidate transmembrane sequence.
Probing the Cry6Aa mechanism of action
Prior to the completion of crystallographic analyses and
the derivation of Cry6Aa structures, we initiated struc-
tural modeling of the Cry6Aa protein. Because the struc-
tural databases contained no proteins with primary
sequence homology with Cry6, more detailed structural
Fig. 6 In vivo pore formation. a Bright field images (upper panels) and fluorescence images (lower panels) of the anterior regions of C. elegans fed
on E. coli transformed with pQE9 vector or plasmids expressing Cry6Aa or Cry5Ba. b Percentage of treated worms showing propidium iodide (PI)
uptake. The p values for the comparison between each toxin and the no-toxin control are shown
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predictions based on known protein structures were im-
possible. We decided, therefore, to employ the Rosetta
modeling program to predict the possible fold of the
Cry6 protein ab initio, producing five de novo models
with no reference to previous structures and five models
using the database structure comparison method. All
models (Additional file 2: Figure S2) exhibited a high
proportion of alpha helix (44–56 %) and very low pro-
portions of beta sheet (1.7–6.9 %). The modeling using
the database structure comparison method returned a
range of distinct structural models. In contrast, the five
de novo models showed a high degree of similarity to
each other, differing mainly in the disposition of the N-
and C-terminal domains with respect to the central do-
main of the long alpha helices. These models predicted a
predominantly alpha helical structure that is highly simi-
lar [the structural alignment of the backbone residues in
the central region of the protein (residues 74–393],
showing an RMSD of 1.78) to the actual structures of
the protein that were subsequently solved through crys-
tallography (see above). Based on the model, we were
able to form a hypothesis that Cry6Aa is a pore-forming
toxin and identify a region that might be involved in this
function as a target for mutagenesis (see below).
Nematode assays as a test for pore-forming activity of
Cry6Aa
Given that our analyses showed structural homology to
toxins such as HlyE and, by analogy, suggested a similar
mechanism of action, we decided to test this hypothesis.
In their work on HlyE, Wallace et al. [40] investigated
the importance of the tongue region by substituting
hydrophobic residues in this part of the sequence with
non-hydrophobic amino acids. They demonstrated the
loss of hemolytic activity. In a parallel experiment, to
disrupt the hydrophobicity of the putative transmem-
brane region of Cry6Aa, we replaced Leu259 with Asp.
The Leu259 residue was chosen because it is a hydro-
phobic residue at the center of the putative membrane-
spanning domain (orange in Fig. 2b). The L259D-
mutant protein was modeled and the change was not
predicted to cause any alteration in the overall fold of
the protein (Additional file 3: Figure S3). The wild-type
Cry6Aa and the L259D mutant, both expressed in E.
coli, were used in the bioassays against C. elegans.
The expression of wild-type and mutant Cry6Aa in E.
coli on IPTG induction was verified by western blotting
(Additional file 4: Figure S4) and cells expressing these
proteins were tested for their activity against C. elegans.
Bioassays showed a striking (Fig. 5a) and significant
(Fig. 5b) reduction in nematode growth following expos-
ure to the wild-type Cry6Aa protein compared to those
feeding on cells transformed with pET28b vector alone
(Fig. 5). In contrast, the L259D mutant revealed no re-
duction in nematode size compared to the controls
(Fig. 5a, b), indicating that this targeted mutation had
eliminated Cry6Aa bioactivity against C. elegans. In
combination with the structural data, this result is
consistent with Cry6 acting as a pore-forming toxin,
with structures and mechanisms of action similar to
Fig. 7 Structural families of B. thuringiensis delta-endotoxins. Representatives of different structural classes of delta-endotoxins of B. thuringiensis are shown.
Cry1Aa [PDB: 1CIY] [52] is a three-domain toxin; Cry6Aa is an alpha helical toxin (this work); Cry34 is an aegerolysin-like protein [PDB: 4JOX] [12] that acts as
a binary toxin with Cry35, a Toxin_10 family protein [PDB: 4JP0] [12]; Cry51 is a member of the Etx/Mtx2 family [PDB: 4PKM] [11]; and Cyt1Aa, a member of
the Bac_thur_toxin family [PDB: 3RON] [53]. All structures are to scale and colored according to secondary structure (alpha helix, red; beta strands, yellow)
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that of the HblB and HlyE toxins that could cause
membrane damage through the insertion of residues
into the head region of the protein, as postulated
from the de novo models.
To test the ability of Cry6Aa to form pores more dir-
ectly, experiments were conducted in vivo using C. ele-
gans fourth-stage hermaphrodites and a live animal
assay for the presence of pores in the intestine [24]. Fol-
lowing exposure of the hermaphrodites to E. coli either
carrying empty pQE9 vector or expressing Cry6Aa or
Cry5Ba, the penetration of ingested propidium iodide
(PI) by intestinal cells was monitored. Under conditions
used, PI gets into intestinal cells exposed to active pore-
forming toxins [24]. As expected, nematodes fed with
empty vector E. coli (pQE9, negative control, no pore-
forming toxin) showed confinement of the PI to the
lumen of the gut, whereas in Cry6Aa- and Cry5Ba (posi-
tive control [24])-treated hermaphrodites, entry of PI
into the intestinal epithelial cell cytoplasm was evident
(Fig. 6a). In these experiments the percentage of her-
maphrodites showing PI entry was quantitated: for
empty vector 1.1 ± 1.1 %, for Cry5B exposure 92 ± 4.4 %,
and for Cry6Aa exposure 41.5 ± 9.7 %. The stronger ef-
fects of Cry5B on PI entry into intestinal cells could be
due to factors such as the absolute toxicity of each pro-
tein, the relative numbers of receptors, or the relative
quantities of the proteins expressed in the cells. None-
theless, Cry6Aa showed significantly higher (p < 0.01 by
ANOVA) pore formation than control (Fig. 6b). There-
fore, based on all our data, we conclude that Cry6Aa is
an active pore-forming toxin.
Conclusions
The elucidated crystal structures for Cry6Aa support a
mechanism of action by pore formation, similar to
toxins such as HblB, and we have demonstrated pore-
forming ability in vivo. The HblB protein and the non-
hemolytic toxin components NheB and NheC (which
also show structural homology to HblB) are derived
from B. cereus strains and induce pore formation and
osmotic lysis of target cells [38], leading to the induction
of diarrhea by this organism. B. thuringiensis is a mem-
ber of the B. cereus sensu lato group of bacilli and, aside
from production of invertebrate-active toxins by B. thur-
ingiensis, the two species are indistinguishable by most
tests [50, 51]. Interestingly, despite the low amino acid
sequence identity, Cry6Aa shares a fold and, we propose,
a mechanism of action with the B. cereus toxins and this
may indicate an adaptation of this HblB protein family
within the B. cereus sensu lato group for activity against
target cells in invertebrates. The known structures of
delta-endotoxins from B. thuringiensis (Cyt family; 3-
domain Cry proteins; the aegerolysin-like Cry34 and
Cry37; the Toxin_10 family Cry35; and the Etx/Mtx2
family Cry45, Cry46, and Cry51) are structurally distinct
from the Cry6 fold (Fig. 7), which represents a new
structural family among insecticidal toxins and a new
paradigm for invertebrate pathogenic toxins. Based on
the present study, we can now further elucidate key fea-
tures of the Cry6Aa toxin that are responsible for its
specificity and mode of action.
Additional files
Additional file 1: Figure S1. Multiple sequence alignment of Cry6Aa
and related toxins. Sequences of full-length Cry6Aa and Cry6Ba were
aligned using the ClustalX program along with the sequences from the
crystal structures of HlyE [PDB: 4PHO], HblB [PDB: 2NRJ], and NheA [PDB:
4K1P]. Residues identical to the Cry6Aa sequence are highlighted in
green; residues identical to Cry6Ba but not in Cry6Aa are highlighted in
blue. Repeat regions in Cry6Aa are highlighted in yellow (repeat motif 1
WATIGAxIQ/E, motif 2 TTNMTSNQY, and motif 3 WYNNSD). The putative
transmembrane region is highlighted in gray with L259 indicated by a
blue asterisk. The “wing” features in the Cry6Aa sequence are indicated
by magenta highlight. (DOCX 19 kb)
Additional file 2: Figure S2. Ab initio models of Cry6Aa. The five
models constructed with reference to database information (db) and five
models constructed entirely de novo (dn) are shown. The predicted
N-terminal domains are shown in light gray and marked “N,” while the
C-terminal domains are shown in black and marked “C.” (PPTX 774 kb)
Additional file 3: Figure S3. Modeled L259D mutant. The full-length
structure (5KUC, magenta) is overlaid with the L259D model (cyan). The
inset illustrates the putative transmembrane loop region with residue 259
shown in stick display. Loops are colored as above for clarity while, for
other regions, the full-length structure is dark gray and the modeled
mutant is light gray. (PPTX 737 kb)
Additional file 4: Figure S4. Western blot of wild-type and L259D mu-
tant Cry6Aa. Expression of the wild-type Cry6Aa (WT) and the L259D mu-
tant confirmed by western blotting. (PPTX 1138 kb)
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